Michael A Whittaker

US Patent:

20040176914, Sep 9, 2004

Filed:

Aug 20, 2003

Appl. No.:

10/645874

Inventors:

Kenneth Buechler - Rancho Santa Fe CA, US
Michael Whittaker - San Diego CA, US

Assignee:

Biosite Incorporated

International Classification:

G01N033/53
G06F019/00
G01N033/48
G01N033/50

US Classification:

702/019000, 435/007100

Abstract:

The present invention describes compositions and methods designed to determine the presence or amount of biologically active natriuretic peptides, or their fragments, in a sample. The degradation of natriuretic peptides is an ongoing process that may be a function of, inter alia, the elapsed time between onset of an event triggering natriuretic peptide release into the tissues and the time the sample is obtained or analyzed; the quantity of proteolytic enzymes present; etc. This degradation can produce circulating amounts of natriuretic peptides having reduced or lost biological function. The present invention provides, inter alia, assays designed to accurately measure biologically active natriuretic peptides, and compositions to inhibit a previously unknown pathway for degradation of natriuretic peptides.

US Patent:

20080045444, Feb 21, 2008

Filed:

Nov 16, 2006

Appl. No.:

11/560425

Inventors:

Michael Whittaker - San Diego CA, US

International Classification:

A61K 38/00
A61K 47/00
A61P 9/00

US Classification:

514002000, 514789000

Abstract:

The present invention describes compositions and methods for treating cardiovascular disease and myocardial infarction using dipeptidyl peptidase inhibitors. Also provided are methods for increasing natriuretic peptide function by administering one or more analogues of B type natriuretic peptide that provide increased stability in the presence of prolyl-specific dipeptidyl.

US Patent:

20090275512, Nov 5, 2009

Filed:

Feb 23, 2009

Appl. No.:

12/391157

Inventors:

MICHAEL WHITTAKER - SAN DIEGO CA, US

Assignee:

Biosite Incorporated - San Diego CA

International Classification:

A61K 38/22
A61P 9/00

US Classification:

514 12

Abstract:

The present invention describes compositions and methods for treating cardiovascular disease and myocardial infarction using dipeptidyl peptidase inhibitors. Also provided are methods for increasing natriuretic peptide function by administering one or more analogues of B type natriuretic peptide that provide increased stability in the presence of prolyl-specific dipeptidyl peptide.

US Patent:

20100324455, Dec 23, 2010

Filed:

May 22, 2010

Appl. No.:

12/785446

Inventors:

Paulo RANGEL - Carlsbad CA, US
Michael A. WHITTAKER - San Diego CA, US
Craig Steven GUNTHER - Mission Viejo CA, US

Assignee:

LASERCURE SCIENCES, INC. - Carlsbad CA

International Classification:

A61B 5/103
A61F 5/00
A43B 13/38

US Classification:

600592, 602 28, 36 43

Abstract:

The present invention provides orthotic devices for use in managing the treatment and prevention of lower extremity injuries, including foot ulcers. In various aspects, the present invention provides foot-worn orthotics which provide for improved compliance monitoring, and methods of their manufacture and use.

US Patent:

20170138932, May 18, 2017

Filed:

Oct 13, 2016

Appl. No.:

15/293262

Inventors:

- SAN DIEGO CA, US
Michael A. Whittaker - San Diego CA, US

Assignee:

ALERE SAN DIEGO, INC. - SAN DIEGO CA

International Classification:

G01N 33/53
G01N 33/543

Abstract:

The present invention describes compositions and methods for treating cardiovascular disease and myocardial infarction using dipeptidyl peptidase inhibitors. Also provided are methods for increasing natriuretic peptide function by administering one or more analogues of B type natriuretic peptide that provide increased stability in the presence of prolyl-specific dipeptidyl peptidases.

US Patent:

20150297666, Oct 22, 2015

Filed:

Nov 19, 2014

Appl. No.:

14/547801

Inventors:

- San Diego CA, US
Michael A. WHITTAKER - San Diego CA, US

International Classification:

A61K 38/05
A61K 45/06
A61K 38/22

Abstract:

The present invention describes compositions and methods for treating cardiovascular disease and myocardial infarction using dipeptidyl peptidase inhibitors. Also provided are methods for increasing natriuretic peptide function by administering one or more analogues of B type natriuretic peptide that provide increased stability in the presence of prolyl-specific dipeptidyl peptidases.